BioSpace News Archive

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable gas-filled intragastric balloon system for the treatment of obesity, announced that the special shareholders meeting for Obalon Stockholders

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced the Company will participate in the upcoming Oppenheimer MedTech, Tools & Diagnostics Summit.

Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced that it will release financial results for the first quarter of 2021 after the close of trading on Tuesday, May 25, 2021. Company management will host a conference call to discuss financial results beginning at 4:30 p.m.

Mustang Bio, Inc. (“Mustang”) today announced that the first patient has been dosed in a clinical trial to establish the safety and feasibility of administering MB-101 (autologous IL13Rα2-CAR T cells) to patients with leptomeningeal brain tumors (e.g., glioblastoma, ependymoma or medulloblastoma).

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30pm EST .

Impel NeuroPharma (Nasdaq: IMPL), a late-stage biopharmaceutical company, today launched Reroute Migraine Relief , an educational initiative which aims to raise awareness of the complexities of migraine, including the underrecognized connection between the brain and gut.

Rafina Innovations Inc., a Medical and Pharmaceutical development company, is pleased to announce C-Pharm’s annual sales for 2020 are $2.7 Million dollars.

I-Mab today announced that the first patient has been dosed in an abbreviated combination clinical study (NCT04202003) of lemzoparlimab (also known as TJC4) with azacitidine (AZA) in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in China.

Ryvu Therapeutics (WSE:RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, announced today its plan to participate in two upcoming investor conferences: UBS 2021 Global Healthcare Virtual Conference and Erste Group Innovation Conference 2021.

The National Organization for Rare Disorders announced that during a recent Board of Directors meeting, Kay Holcombe was elected as Chair and Dennis Jackman joined as a new Board member.